Imaging Cholinergic Receptors in the Brain by Positron Emission Tomography

JJ Zhang, H Fu, R Lin, J Zhou, A Haider… - Journal of Medicinal …, 2023 - ACS Publications
Cholinergic receptors represent a promising class of diagnostic and therapeutic targets due
to their significant involvement in cognitive decline associated with neurological disorders …

Evaluation of [18F]RoSMA-18-d6 as a CB2 PET Radioligand in Nonhuman Primates

A Haider, L Wang, L Gobbi, Y Li… - ACS chemical …, 2023 - ACS Publications
The cannabinoid type 2 receptor (CB2) has been implicated in a variety of central and
peripheral inflammatory diseases, prompting significant interest in the development of CB2 …

Development of a selective and high affinity radioligand,[3H] VU6013720, for the M4 muscarinic receptor

A Qi, HE Kling, N Billard, AL Rodriguez, L Peng… - Molecular …, 2023 - ASPET
M4 muscarinic receptors are highly expressed in the striatum and cortex, brain regions that
are involved in diseases such as Parkinson's disease, schizophrenia, and dystonia. Despite …

Discovery of 2-Methyl-5-(1H-pyrazol-4-yl)pyridines and Related Heterocycles as Promising M4 mAChR Positive Allosteric Modulators for the Treatment of …

B Liu, G Thompson, M Jörg, N Barnes… - Journal of Medicinal …, 2024 - ACS Publications
The M4 muscarinic acetylcholine receptor (mAChR) is a biological target for neurocognitive
disorders. Compound 1 is an ago-PAM for the M4 mAChR. Herein, we report the design …

Recessive CHRM5 variant as a potential cause of neurogenic bladder

S Schneider, L Schierbaum… - American Journal of …, 2023 - Wiley Online Library
Neurogenic bladder is caused by disruption of neuronal pathways regulating bladder
relaxation and contraction. In severe cases, neurogenic bladder can lead to vesicoureteral …

Design, synthesis and evaluation of novel 2-phenyl-3-(1H-pyrazol-4-yl) pyridine positive allosteric modulators for the M4 mAChR

M Jörg, ET van der Westhuizen, Y Lu, KHC Choy… - European Journal of …, 2023 - Elsevier
Translation of muscarinic acetylcholine receptor (mAChR) agonists into clinically used
therapeutic agents has been difficult due to their poor subtype selectivity. M 4 mAChR …